Publications by authors named "Sarah M Matejka"
The COVID-19 pandemic has highlighted the need for mucosal vaccines as breakthrough infections, short-lived immune responses and emergence of new variants have challenged the efficacy provided by the first generation of vaccines against SARS-CoV-2 viruses. M2SR SARS-CoV-2, an M2-deleted single-replication influenza virus vector modified to encode the SARS-CoV-2 receptor binding domain, was evaluated following intranasal delivery in a hamster challenge model for protection against Wuhan SARS-CoV-2. An adjuvanted inactivated SARS-CoV-2 whole virus vaccine administered intramuscularly was also evaluated.
View Article and Find Full Text PDFArticle Synopsis
- - Current COVID-19 vaccines protect against hospitalization and death but struggle to prevent initial infection and transmission, with common breakthrough infections from new variants despite updated boosters.
- - Researchers developed a dual vaccine, SARS-CoV-2 M2SR, using an intranasal approach to boost mucosal immunity, showing promising results in mice with high levels of protective antibodies against both SARS-CoV-2 and influenza.
- - The M2SR vaccine demonstrated strong immune responses to the original strain and variants like Delta and Omicron, suggesting it could provide better protection against respiratory viruses compared to current vaccines.